Scilex Holding Co

Scilex focuses on developing and commercializing non-opioid treatments for acute and chronic pain conditions. Its commercial portfolio includes ZTlido, a prescription topical lidocaine delivery system for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution indicated for the acute treatment of migraine in adults; and GLOPERBA, a liquid oral medication for preventing gout flares. The company also advances investigational candidates targeting sciatica, acute lower back pain, and fibromyalgia. Its treatments serve adult patients suffering from severe pain disorders, distributed through national and regional wholesalers and retail pharmacies following prescriptions from physicians and specialists.

Commercial operations and marketing efforts are centered in the United States, with regulatory filings also extending into Canada. Product manufacturing is conducted internationally, with topical patch production handled by a partner in Japan. Commercial distribution relies on a nationwide network of pharmacies, healthcare providers, and regional wholesalers across the country.

Summary of the business section of Scilex's latest annual report, written by StockData.

“As of December 31, 2025, we had approximately 34 full-time employees, including three employees who have M.D.s or Ph.D.s.”